Role of Red Blood Cells in Cardiovascular Disease
Launched by KAROLINSKA INSTITUTET ·
Trial Information
Current as of September 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how red blood cells (the cells that carry oxygen in your blood) affect heart health, especially in people with type 2 diabetes. Researchers have found that red blood cells normally help protect the heart during low oxygen conditions, like during a heart attack, by sending important chemical signals. However, in people with type 2 diabetes, these red blood cells don’t work properly and may cause damage to the heart and blood vessels. The study aims to better understand these processes and explore new ways to treat heart problems by targeting the way red blood cells function.
People who have had a heart attack, have type 2 diabetes, or are healthy volunteers may be eligible to take part. Participants will have their blood collected to study the red blood cells in the lab, and researchers will look at how these cells affect heart and blood vessel function. This study is currently recruiting, and anyone interested can ask their doctor if joining might be right for them. The findings could lead to new treatments that help protect the heart, especially for people with diabetes.
Gender
ALL
Eligibility criteria
About Karolinska Institutet
Karolinska Institutet is a renowned medical university located in Sweden, recognized for its commitment to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the institution focuses on translating scientific discoveries into effective treatments and therapies, emphasizing patient-centered approaches. With a strong emphasis on collaboration and interdisciplinary research, Karolinska Institutet plays a pivotal role in addressing global health challenges and improving patient outcomes, leveraging its extensive network of experts and state-of-the-art facilities to drive clinical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
John Pernow, MD
Principal Investigator
Karolinska Institutet
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported